Diseases [C] » Cardiovascular Diseases [C14] » Heart Diseases » Myocardial Ischemia
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Myocardial Ischemia
Description
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION). MeSH
Hierarchy View
Subtype Terms (6)
Acute Coronary Syndrome
145 drugs (97 approved, 48 experimental)
Angina Pectoris
109 drugs (56 approved, 53 experimental)
Coronary Disease
242 drugs (147 approved, 95 experimental)
Myocardial Infarction
291 drugs (171 approved, 120 experimental)
Myocardial Reperfusion Injury
23 drugs (17 approved, 6 experimental)
Phase 4 Indicated Drugs (45)
Phase 2 Indicated Drugs (34)
Other Experimental Indicated Drugs (23)
Organization Involved with Phase 4 Indications (246)
Ada and Hagbart Waages Humanitarian and Charity Foundation
Alf and Aagot Helgesens Research Foundation
Ankara Yildirim Beyazıt University
ANMCO Italian Association of Hospital Cardiologist
Aristotle University of Thessaloniki
Associations for Establishment of Evidence in Interventions
Atlanta Heart Specialists, LLC
Bio-Inova Life Sciences International
Cardiovascular Institute of the South Clinical Research Corporation
CardioVascular Research Foundation, Korea
Centro de estudios en Cardiologia Intervencionista
China Academy of Chinese Medical Sciences
Chinese Academy of Medical Sciences
Clinical Hospital Center Zemun
Daewoong Pharmaceutical Co. LTD.
D'Annunzio University of Chieti–Pescara
Fundação de Amparo à Pesquisa do Estado de São Paulo
German Federal Ministry of Education and Research
Guangdong Provincial Hospital of Traditional Chinese Medicine
Haugaard, Steen Bendix, M.D., DMSc
Heart and Stroke Foundation of Canada
Hospital Alessandro Manzoni Lecco
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Imam Abdulrahman Bin Faisal University
I.M. Sechenov First Moscow State Medical University
Instituto Mexicano del Seguro Social
Italian Society of Invasive Cardiology
Japan Cardiovascular Research Foundation
Jiangsu Kangyuan Pharmaceutical Co. Ltd
King Fahad Armed Forces Hospital
Kyoto Prefectural University of Medicine
Lepu Medical Technology (Beijing) Co., Ltd.
Methodist Cancer Center, Houston, Texas
National Cheng Kung University
National Health and Medical Research Council, Australia
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of General Medical Sciences (NIGMS)
National Natural Science Foundation of China
Pauls Stradins Clinical University Hospital
People's Liberation Army of China
Pontificia Universidad Catolica de Chile
Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Samjin Pharmaceutical Co., Ltd.
Shanghai Hutchison Pharmaceuticals Limited
Shanghai MicroPort Medical (Group) Co., Ltd.
Shanghai Xuhui District Central Hospital
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Taipei Veteran General hospital
The Baruch Padeh Medical Center, Poriya
The Norwegian Council on Cardiovascular Disease
The University of Texas, Dallas
Ukrainian Medical Stomatological Academy
University Hospital of Limerick
University of California, Los Angeles
University of California, San Francisco
University of Campania Luigi Vanvitelli
University of Modena and Reggio Emilia
University of Roma La Sapienza
University of Texas, San Antonio
Vita-Salute University of Milano. Italy
WanBangDe Pharmaceutical Group Co.,Ltd.
Organization Involved with Phase 3 Indications (187)
Advanced Accelerator Applications
Andalusian Initiative for Advanced Therapies
Andalusian Initiative in Advanced Therapies
Assistance Publique - Hôpitaux de Paris
Associazione Nazionale Medici Cardiologi Ospedalieri
Boston Health and Hospitals Department
Catharina Ziekenhuis Eindhoven
Centers for Disease Control and Prevention (CDC)
Centro Cardiológico del Caribe, Columbia
Dr. Negrin University Hospital
Foundation to Promote Research into Functional Vitamin B12 Deficiency, Bergen, Norway
Greater Baltimore Medical Center
Institute of Cardiology, Warsaw, Poland
Institut National de la Santé Et de la Recherche Médicale, France
Juvenile Diabetes Research Foundation
King Faisal Specialist Hospital
Los Angeles Biomedical Research Institute
Maryland Medical Research Institute
National Cancer Institute (NCI)
National Heart Institute, Bach Mai Hospital, Vietnam
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
National Institutes of Health (NIH)
New England Research Institutes
Norwegian Heart and Lung Patient Organisation
Novosibirsk Research Institute of Circulation Pathology
Oklahoma Medical Research Foundation
Pacific Health Research Institute
Palo Alto Medical Research Foundation
Pontifícia Universidade Católica do Paraná
Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)
Salt Lake Clinic Research Foundation
Servicio de Evaluación. Servicio Canario de Salud. Spain
Shahid Beheshti University of Medical Sciences
SMT KASHIBAI NAVALE MEDICAL COLLEGE
Steno Diabetes Center Copenhagen
St. Joseph Hospital Health Center
Taichung Veterans General Hospital
Translational Research Informatics Center, Kobe, Hyogo, Japan
University Hospital of North Norway
University of Alabama, Birmingham
University of California, Berkeley
University of California, Davis
University of California, San Diego
University of Colorado, Denver
University of Las Palmas de Gran Canaria
University of North Carolina at Chapel Hill
University of Rome Tor Vergata
University of Southern California
University of Western Brittany
Venezuelan Foundation of Heart Failure
Virginia Commonwealth University
Zhejiang Hisun Pharmaceutical Co. Ltd.
ZonMw: The Netherlands Organisation for Health Research and Development
Organization Involved with Phase 2 Indications (96)
Cardiovascular Cell Therapy Research Network
Cardiovascular Imaging Technologies
Catholic University of Sacred Heart, Rome
Centre for Digestive Diseases, Australia
Changchun University of Chinese Medicine
Fibrex Medical Research & Development GmbH
Foundation for Biomedical Research and Innovation
Fundacion Investigacion y Desarrollo
German Center for Cardiovascular Research e. V. (DZHK)
Hellenic Cardiovascular Research Society
Ivy Institute of Stem Cells Co. Ltd
Jacksonville Center for Clinical Research
National Institute of Mental Health (NIMH)
Papworth Hospital NHS Foundation Trust
Platelet and Thrombosis Research L.L.C
Polpharma Foundation for Development of Polish Pharmacy and Medicine
Rawalpindi Institute of Cardiology
Richardson Centre for Functional Foods and Nutraceuticals
Shifa Tameer-e-Millat University
Organization Involved with Phase 1 Indications (19)
Organization Involved with Other Experimental Indications (68)
Beijing Municipal Health Bureau
Canadian Anesthesiologists' Society
Canadian Collaborative Research Network
Chinese People's Armed Police Forces
Chinese University of Hong Kong
Conselho Nacional de Desenvolvimento Científico e Tecnológico
General Hospital of Chinese Armed Police Forces
Guangzhou University of Chinese Medicine
Hamilton Health Sciences Corporation
Henan Institute of Cardiovascular Epidemiology
Medical Research Foundation, Oregon
New York City Health and Hospitals Corporation
Oregon Health and Science University
Rio de Janeiro State University
Saint Francis Memorial Hospital
Shaanxi Provincial People's Hospital
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
